Trade

with

Galectin Therapeutics Inc
(NASDAQ: GALT)
AdChoices
5.09
+0.35
+7.38%
After Hours :
5.09
0.00
0.00%

Open

4.78

Previous Close

4.74

Volume (Avg)

145.77k (668.46k)

Day's Range

4.75-5.09

52Wk Range

4.28-19.11

Market Cap.

112.20M

Dividend Rate ( Yield )

-

Beta

1.69

Shares Outstanding

22.04M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 0

    • Net Income

    • -12.09M

    • Market Cap.

    • 112.20M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.69

    • Forward P/E

    • -16.37

    • Price/Sales

    • -

    • Price/Book Value

    • 4.46

    • Price/Cash flow

    • -10.88

      • EBITDA

      • -12.08M

      • Return on Capital %

      • -80.23

      • Return on Equity %

      • -149.03

      • Return on Assets %

      • -80.23

      • Book Value/Share

      • 1.14

      • Shares Outstanding

      • 22.04M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 32.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 64.72

            • Pre-Tax Margin

            • -

            • 13.77

            • Net Profit Margin

            • -

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 16.07

              • 1.52

              • Quick Ratio

              • 16.03

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.38

              • 1.91

              • Book Value/Share

              • 1.14

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -6.24

                • 65.79

                • P/E Ratio 5-Year High

                • -23.43

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.77

                • 19.71

                • Price/Sales Ratio

                • -

                • 3.69

                • Price/Book Value

                • 4.46

                • 3.46

                • Price/Cash Flow Ratio

                • -10.88

                • 22.12

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -149.03

                        (-)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • -80.23

                        (-491.80)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • -149.03

                        (-)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • -

                      • 27.79k

                      • Inventory Turnover

                      • -

                      • 1.80

                      • Asset Turnover

                      • -

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -12.10M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -10.88
                      Ownership

                      Institutional Ownership

                      18.99%

                      Top 10 Institutions

                      13.32%

                      Mutual Fund Ownership

                      7.32%

                      Float

                      92.71%

                      5% / Insider Ownership

                      23.75%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Total Stock Mkt Idx

                      •  

                        345,606

                      • 0.00

                      • 1.57

                      • iShares Russell 2000 (AU)

                      •  

                        266,000

                      • -1.47

                      • 1.14

                      • Vanguard Extended Market Index Fund

                      •  

                        190,648

                      • 4.85

                      • 0.86

                      • iShares Russell 2000 Growth

                      •  

                        124,033

                      • 0.34

                      • 0.53

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        80,065

                      • 0.00

                      • 0.36

                      • CREF Stock

                      •  

                        62,656

                      • 19.92

                      • 0.28

                      • iShares Micro-Cap

                      •  

                        54,560

                      • 0.00

                      • 0.23

                      • Delaware Healthcare Fund

                      •  

                        40,000

                      • 0.00

                      • 0.18

                      • The Vanguard - Total Stk Mkt Idx Trust. CF

                      •  

                        30,001

                      • 209.26

                      • 0.14

                      • CS (Lux) Biotechnology Equity Fund

                      •  

                        30,000

                      • 0.00

                      • 0.14

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Cormorant Asset Management, LLC

                      •  

                        800,000

                      • +129.89%

                      • 3.63

                      • Vanguard Group, Inc.

                      •  

                        501,365

                      • +13.49%

                      • 2.28

                      • BlackRock Fund Advisors

                      •  

                        453,412

                      • +640.86%

                      • 2.06

                      • Baker Bros Advisors LLC

                      •  

                        300,000

                      • -40.00%

                      • 1.36

                      • Davidson D A & Co

                      •  

                        194,158

                      • +28.89%

                      • 0.88

                      • Neuberger Berman LLC

                      •  

                        163,010

                      • +1.02%

                      • 0.74

                      • Allianz Global Investors

                      •  

                        139,285

                      • +57.10%

                      • 0.63

                      • Geode Capital Management, LLC

                      •  

                        109,937

                      • +48.42%

                      • 0.50

                      • Susquehanna Financial Group, LLLP

                      •  

                        103,343

                      • -43.58%

                      • 0.47

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Distressed

                      Style

                      Small Core

                      Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galec...moretin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current ...moretreatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include major multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.lessless

                      Key People

                      Dr. Peter G. Traber,M.D.

                      CEO/Chief Medical Officer/Director/President

                      James C. Czirr

                      Chairman of the Board/Director

                      Rod D. Martin

                      Director/Vice Chairman of the Board

                      Mr. Jack W. Callicutt

                      CFO/Chief Accounting Officer

                      Eliezer Zomer,PhD

                      Executive VP, Divisional

                      • Galectin Therapeutics Inc

                      • 4960 Peachtree Industrial Boulevard

                      • Norcross, GA 30071

                      • USA.Map

                      • Phone: +1 678 620-3186

                      • Fax: +1 770 864-1327

                      • galectintherapeutics.com

                      Incorporated

                      2001

                      Employees

                      6

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: